WellMedr scores a 42 on our Value Score. These are the top-ranked GLP-1 deals we'd point you to instead — every one scored on the same six factors, with the teaser-rate traps flagged so you pay the honest lower price.
!Pricing to watch. An established national telehealth marketplace with the widest real brand-name GLP-1 access in the ranking — Wegovy (pen and pill), Zepbound, Ozempic and Mounjaro — plus provider-by-provider price transparency.
✓No teaser step-up. A LegitScript-certified, physician-supervised program that's one of the few offering a genuine oral GLP-1 tablet alongside injectable — with transparent flat monthly pricing and no insurance required.
!Pricing to watch. A broad, physician-led menu — compounded and oral GLP-1 plus an advertised brand-name lane under a named plastic surgeon — with transparent, all-inclusive pricing from ~$194/mo (annual) across all 50 states.
✓No teaser step-up. GOAL.MD is a St. Louis-based telehealth platform offering compounded semaglutide alongside brand-name bridges to Ozempic, Wegovy, and Zepbound. Its standout is a manual-renewal model — no auto-billing
From $79/mo (microdose tier, 12-month plan, compounded)
Save ~94%
!Pricing to watch. Good Girl Rx (Good Girl LLC) offers compounded semaglutide and tirzepatide in injectable, microdose, and oral dissolving tablet (ODT) formats.
⚠FDA warning letter. The FDA issued Good Girl LLC dba GoodGirlRX a warning letter in February 2026. Check it on the FDA database.
$289/mo cash month-to-month · $169/mo on a 12-month prepay
Save ~93%
!Pricing to watch. The widest medication bench in this ranking — compounded, brand-name and oral — priced off a membership whose $99 headline only holds if you commit for months.
Ranked by our Value Score — our editorial judgment per the methodology. “Save” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Assume any provider we list may compensate us — it never changes a Value Score. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.